Recently released data show that this year’s COVID-19 and Influenza vaccines both reduce the risk of acute respiratory illness and hospitalizations in older adults. Vaccine effectiveness of 2024–2025 COVID-19 vaccine was 45%–46% against hospitalizations among adults aged 65 years and older, compared with not receiving a 2024–2025 vaccine dose. This was based on data from two networks evaluating vaccine effectiveness, VISION and IVY networks, that collect information from hospitalized individuals on their vaccination status and the type of infections.
Interim 2024–2025 seasonal influenza vaccine effectiveness estimates were calculated from four American vaccine effectiveness networks. Among adults aged 65 years and older, vaccine effectiveness against any influenza-associated acute respiratory infections was 51% in outpatient settings. And it was 38% (IVY) and 57% (VISION) against hospitalization. As of February 3, 2025, testing for the strains of virus causing human infections found that they match with those strains covered in this year's vaccine.
Details of these studies, along with additional information on VE for children and adults can be found at MMWR Feb 27, 2025.